Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 9, 1096-1104, September 2007; doi:10.1634/theoncologist.12-9-1096
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lally, B. E.
Right arrow Articles by Perry, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lally, B. E.
Right arrow Articles by Perry, M. C.

Lung Cancer

Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?

Brian E. Lallya, James J. Urbanica, A. William Blackstocka, Antonius A. Millerb, Michael C. Perryc

Departments of aRadiation Oncology and bMedical Oncology, Wake Forest University Health Sciences, Winston-Salem, North Carolina, USA; cThe Ellis Fischel Cancer Center/University of Missouri, Columbia, Missouri, USA

Correspondence: Michael C. Perry, M.D., M.S., M.A.C.P., Ellis Fischel Cancer Center/University of Missouri, 115 Business Loop 70 West, Columbia, Missouri 65203, USA. Telephone: 573-882-4979; Fax: 573-884-6050; e-mail: PerryM{at}health.missouri.edu

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Twenty-five years ago, small cell lung cancer was widely considered to be the next cancer added to the list of "curable cancers." This article attempts to summarize the progress made toward that goal since then. Clinical trials have provided landmarks in the therapy of limited-stage small cell lung cancer (LS-SCLC). These are: (a) the proof that thoracic radiation therapy adds to systemic chemotherapy, (b) the superiority of twice-daily radiation therapy over daily fractionation, and (c) the need for prophylactic central nervous system radiation (prophylactic cranial irradiation). Each of these innovations adds about 5%–10% to the overall survival rate.

In extensive-stage disease, irinotecan plus cisplatin may be a possible alternative to the "standard" etoposide–cisplatin chemotherapy doublet, but there has been little progress otherwise. It is imperative that, whenever possible, patients be given the opportunity to participate in future clinical trials so that the survival for these patients can continue to improve.




This article has been cited by other articles:


Home page
 JCOHome page
Q.-T. X. Le, J. Moon, M. Redman, S. K. Williamson, P. N. Lara Jr, Z. Goldberg, L. E. Gaspar, J. J. Crowley, D. F. Moore Jr, and D. R. Gandara
Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222
J. Clin. Oncol., June 20, 2009; 27(18): 3014 - 3019.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement